DZ2376A1 - Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. - Google Patents
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.Info
- Publication number
- DZ2376A1 DZ2376A1 DZ970226A DZ970226A DZ2376A1 DZ 2376 A1 DZ2376 A1 DZ 2376A1 DZ 970226 A DZ970226 A DZ 970226A DZ 970226 A DZ970226 A DZ 970226A DZ 2376 A1 DZ2376 A1 DZ 2376A1
- Authority
- DZ
- Algeria
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- sulfonamide derivatives
- derivatives process
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9626377.7A GB9626377D0 (en) | 1996-12-19 | 1996-12-19 | Novel compounds |
GBGB9700901.3A GB9700901D0 (en) | 1997-01-17 | 1997-01-17 | Novel compounds |
GBGB9722757.3A GB9722757D0 (en) | 1997-10-27 | 1997-10-27 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ2376A1 true DZ2376A1 (fr) | 2002-12-28 |
Family
ID=27268644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ970226A DZ2376A1 (fr) | 1996-12-19 | 1997-12-07 | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
Country Status (31)
Country | Link |
---|---|
US (2) | US6423717B1 (fr) |
EP (1) | EP0946539B1 (fr) |
JP (1) | JP2001506646A (fr) |
KR (1) | KR20000069554A (fr) |
CN (1) | CN1246116A (fr) |
AP (1) | AP1277A (fr) |
AR (1) | AR010795A1 (fr) |
AT (1) | ATE247099T1 (fr) |
AU (1) | AU729056B2 (fr) |
BG (1) | BG103530A (fr) |
BR (1) | BR9713734A (fr) |
CA (1) | CA2275492A1 (fr) |
CZ (1) | CZ220399A3 (fr) |
DE (1) | DE69724142T2 (fr) |
DZ (1) | DZ2376A1 (fr) |
EA (1) | EA002351B1 (fr) |
ES (1) | ES2203831T3 (fr) |
HU (1) | HUP0000658A3 (fr) |
ID (1) | ID22821A (fr) |
IL (1) | IL130297A0 (fr) |
MA (1) | MA24426A1 (fr) |
NO (1) | NO993003D0 (fr) |
NZ (1) | NZ335970A (fr) |
OA (1) | OA11066A (fr) |
PE (1) | PE46899A1 (fr) |
PL (1) | PL334337A1 (fr) |
SK (1) | SK80899A3 (fr) |
TR (1) | TR199901361T2 (fr) |
TW (1) | TW418205B (fr) |
UY (1) | UY24819A1 (fr) |
WO (1) | WO1998027081A1 (fr) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
CN1087294C (zh) * | 1997-07-11 | 2002-07-10 | 史密丝克莱恩比彻姆有限公司 | 新化合物 |
ES2317688T3 (es) | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
EP1248607A4 (fr) * | 1999-12-21 | 2004-10-06 | Smithkline Beecham Corp | Antagonistes des recepteurs de l'urotensine ii |
SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
US6818639B2 (en) | 2000-07-21 | 2004-11-16 | Biovitrum Ab | Pharmaceutical combination formulation and method of treatment with the combination |
US6399617B1 (en) | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
DE60142914D1 (de) * | 2000-09-18 | 2010-10-07 | Toa Eiyo Ltd | N-substituierte benzothiophensulfonamid-derivate |
US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
JP2004517826A (ja) * | 2000-11-21 | 2004-06-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Cns障害の治療において有用なイソキノリン誘導体 |
US7132546B2 (en) | 2000-12-22 | 2006-11-07 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
EP1389194A2 (fr) * | 2001-04-27 | 2004-02-18 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de bace |
US6743796B2 (en) | 2001-05-07 | 2004-06-01 | Wyeth | Piperazinyl-isatins |
WO2002090337A1 (fr) * | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
JP2004535390A (ja) * | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
JP2005508852A (ja) * | 2001-05-07 | 2005-04-07 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
WO2002089793A1 (fr) * | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
AR033879A1 (es) | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
GB0111186D0 (en) * | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
RS88803A (en) * | 2001-05-11 | 2007-02-05 | Biovitrum Ab., | Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders |
IL158593A0 (en) | 2001-05-11 | 2004-05-12 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
SK16052003A3 (en) | 2001-06-07 | 2004-10-05 | Hoffmann La Roche | New indole derivatives with 5-HT6 receptor affinity |
WO2002100822A1 (fr) * | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Composants de sulfonamide substitues, procede d'utilisation de ceux-ci comme medicaments dans le traitement de troubles cns, de l'obesite et du diabete de type ii |
CA2450245A1 (fr) | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Derives de 4-piperazinylindole a affinite avec les recepteurs 5-ht6 |
US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
JP2005527463A (ja) * | 2001-08-07 | 2005-09-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Cns疾患を治療するための5−ht6受容体アフィニティーを有する3−アリールスルホニル−7−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン |
JP4187650B2 (ja) * | 2001-08-10 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6レセプター親和性を有するアリールスルホニル誘導体 |
WO2003022272A1 (fr) * | 2001-09-05 | 2003-03-20 | Eisai C0. Ltd. | Agents stimulant l'appetit et remedes contre l'anorexie |
SE0103644D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
ATE429916T1 (de) * | 2001-11-09 | 2009-05-15 | Biovitrum Ab Publ | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme |
EA200400707A1 (ru) | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
US7074788B2 (en) | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
MXPA04004981A (es) * | 2001-11-30 | 2004-08-11 | Hoffmann La Roche | Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma. |
WO2003066056A1 (fr) * | 2002-02-05 | 2003-08-14 | Glaxo Group Limited | Technique de stimulation de la croissance neuronale |
IL162859A0 (en) * | 2002-02-05 | 2005-11-20 | Novo Nordisk As | Novel aryl-and heteroarylpiperazines |
PL371344A1 (en) * | 2002-02-13 | 2005-06-13 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
US20050090485A1 (en) * | 2002-02-13 | 2005-04-28 | Bromidge Steven M. | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders |
JP2005517705A (ja) * | 2002-02-13 | 2005-06-16 | グラクソ グループ リミテッド | ベンゼンスルホンアミド誘導体ならびにドーパミンd3およびd2受容体リガンドとしてのその使用 |
MY138836A (en) | 2002-03-27 | 2009-07-31 | Glaxo Group Ltd | Quinoline derivatives and their use as 5-ht6 receptor ligands |
US20040142948A1 (en) * | 2002-05-07 | 2004-07-22 | Dashyant Dhanak | Sulfonamides |
UA76877C2 (uk) * | 2002-05-13 | 2006-09-15 | Ф.Хоффманн-Ля Рош Аг | Похідні бензоксазину як 5-нт6 модулятори і їх застосування |
NZ552282A (en) * | 2002-06-20 | 2008-07-31 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
EP1897876A3 (fr) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central |
CA2501172A1 (fr) | 2002-10-18 | 2004-08-29 | F. Hoffmann-La Roche Ag | Indoles 4-piperazinyle benzenesulfonyle presentant une affinite pour le recepteur 5-ht6 |
AU2003291262A1 (en) * | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
AU2003295408A1 (en) * | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
EA011009B1 (ru) | 2003-01-14 | 2008-12-30 | Арена Фармасьютикалз Инк. | 1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
WO2004072087A2 (fr) * | 2003-02-13 | 2004-08-26 | Lanxess Deutschland Gmbh | Complexes metalliques servant de composes photoabsorbants dans la couche d'information de supports de donnees optiques |
AU2004212985B2 (en) * | 2003-02-20 | 2010-10-14 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
WO2004087654A2 (fr) * | 2003-03-31 | 2004-10-14 | Janssen Pharmaceutica N.V. | Inhibiteurs de phospholipase c a utiliser pour le traitement de troubles inflammatoires |
US6946466B2 (en) * | 2003-04-10 | 2005-09-20 | Schering Ag | Aromatic sulfonamides as peroxynitrite-rearrangement catalysts |
US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
EP1694663A1 (fr) * | 2003-12-19 | 2006-08-30 | Biovitrum Aktiebolag | Nouveaux derives de benzofurane, pouvant etre utilises dans la prophylaxie ou le traitement des affections associees au recepteur de 5-ht6 |
US7381728B2 (en) * | 2004-07-28 | 2008-06-03 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
BRPI0516749B8 (pt) * | 2004-09-30 | 2021-05-25 | Hoffmann La Roche | composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivos |
JP4904277B2 (ja) | 2004-10-14 | 2012-03-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンd3受容体の調節に応答する障害の治療に好適な複素環化合物 |
CA2583333C (fr) | 2004-10-14 | 2013-05-14 | Abbott Gmbh & Co. Kg | Composes d'azabicycloheptyle destines au traitement des troubles reagissant a une modulation du recepteur de dopamine d<sb>3</sb> |
WO2006062481A1 (fr) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central |
EP1676841A1 (fr) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Composés substitués type sulphonamide d'indazole ou sulphonamide de 2,3-dihydroindole, leur préparation et leur utilisation comme médicaments |
WO2006075808A1 (fr) * | 2005-01-12 | 2006-07-20 | Inje University | Composition pharmaceutique comprenant un inhibiteur de p25/cdk5 permettant de prevenir ou de traiter une maladie neurodegenerative |
KR101286569B1 (ko) | 2005-07-04 | 2013-07-23 | 하이 포인트 파마슈티칼스, 엘엘씨 | 신규 약제 |
ATE452885T1 (de) | 2005-08-12 | 2010-01-15 | Suven Life Sciences Ltd | Aminoarylsulfonamidderivate als funktionelle 5- ht6-liganden |
KR101250820B1 (ko) | 2005-08-16 | 2013-04-04 | 수벤 라이프 사이언시스 리미티드 | 개선된 로사르탄 제조 방법 |
WO2007076875A2 (fr) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Composes agissant sur le transporteur de la serotonine |
PE20080176A1 (es) | 2006-03-31 | 2008-04-25 | Glaxo Group Ltd | Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs) |
CA2648892A1 (fr) | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Composes heterocycliques pouvant etre utilises pour traiter des troubles qui repondent a la modulation du recepteur de serotonine 5ht6 |
WO2007118899A1 (fr) * | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Arylsulfones hétérocycliques pouvant être employés pour traiter des troubles qui répondent à la modulation du récepteur de la sérotonine 5ht6 |
EP2038256A1 (fr) | 2006-05-23 | 2009-03-25 | TransTech Pharma, Inc | 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine et son utilisation comme medicament |
DK2079732T3 (da) | 2006-05-29 | 2012-01-23 | High Point Pharmaceuticals Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazin, dets salte og solvater og dets anvendelse som histamin H3-receptorantagonister |
EP2086329B1 (fr) | 2006-10-26 | 2014-07-23 | The Arizona Board of Regents on behalf of the University of Arizona | Modulateurs d'aquaporine et procédés pour leur utilisation pour le traitement d'un oedème et d'un déséquilibre de fluides |
DK2114878T3 (da) | 2007-01-08 | 2011-03-14 | Suven Life Sciences Ltd | 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander |
MX2009007416A (es) * | 2007-01-10 | 2009-07-17 | Hoffmann La Roche | Derivados de sulfonamida como inhibidores de quimasa. |
BRPI0809142A2 (pt) | 2007-03-23 | 2014-08-26 | Abbott Gmbh & Co Kg | Compostos de azetidina adequados para tratar desordens que respondem à modulação do receptor 5-ht6 de serotonina |
CA2683124C (fr) | 2007-05-03 | 2012-09-25 | Suven Life Sciences Limited | Composes aminoalcoxy aryl sulfonamides et leur utilisation en tant que ligands 5-ht<sb>6</sb> |
EP2014656A3 (fr) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Nouveaux antagonistes d'hétéocycliques h3 |
EP2016943B1 (fr) * | 2007-07-19 | 2011-02-23 | Laboratorios del Dr. Esteve S.A. | Composés de sulfamide de tetrahydro-quinoline substituée, leur préparation et utilisation en tant que médicament |
US7964627B2 (en) | 2007-10-26 | 2011-06-21 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-HT6 ligands |
CL2008003232A1 (es) * | 2007-11-02 | 2009-11-27 | Abbott Gmbh & Co Kg | Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad. |
EP2254564A1 (fr) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
WO2009123714A2 (fr) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb> |
US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
CN102089278A (zh) * | 2008-06-11 | 2011-06-08 | Irm责任有限公司 | 用于治疗疟疾的化合物和组合物 |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
BRPI0913736A2 (pt) | 2008-09-17 | 2023-04-11 | Suven Life Sciences Ltd | Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso central |
WO2010062321A1 (fr) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées |
UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
KR101073703B1 (ko) | 2009-04-07 | 2011-10-14 | 한국화학연구원 | 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물 |
EP2432770A1 (fr) | 2009-04-30 | 2012-03-28 | Abbott GmbH & Co. KG | Composés de benzenesulfonanilide pour le traitement de troubles répondant à la modulation du récepteur 5-ht6 de la sérotonine |
JP2012525355A (ja) * | 2009-04-30 | 2012-10-22 | アボット ゲーエムベーハー ウント カンパニー カーゲー | セロトニン5−ht6受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物 |
WO2010125134A1 (fr) | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg | Composés n-phényl-(pipérazinyl ou homopipérazinyl)- benzènesulfonamide ou benzènesulfonyl-phényl-(pipérazine ou homopipérazine) adaptés au traitement de troubles répondant à la modulation du récepteur 5-ht6 de la sérotonine |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
EA022043B1 (ru) | 2010-01-05 | 2015-10-30 | Сувен Лайф Сайенсиз Лимитед | Сульфоновые соединения в качестве лигандов 5-htрецептора |
EA201390421A1 (ru) | 2010-09-22 | 2013-09-30 | Арена Фармасьютикалз, Инк. | Модуляторы рецептора gpr119 и лечение связанных с ним нарушений |
WO2012059432A1 (fr) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 |
WO2012059431A1 (fr) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine |
ES2413911B1 (es) * | 2011-12-15 | 2014-05-14 | Universidad De Zaragoza | Agente inhibidor de la agregación del peptido beta amiloide. |
EP2828238B1 (fr) | 2012-03-20 | 2016-05-25 | Adamed Sp. z o.o. | Dérivés de sulfonamide de la benzylamine pour le traitement de maladies du système nerveux central (snc) |
KR102334260B1 (ko) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 및 alk2 억제제 및 이들의 사용 방법 |
PL3027613T3 (pl) | 2013-07-25 | 2018-10-31 | Uniwersytet Jagielloński | Pochodne pirolochinoliny jako antagonisty 5-HT6, sposób wytwarzania i ich zastosowanie |
EP3134392B1 (fr) | 2014-04-19 | 2019-01-02 | Sunshine Lake Pharma Co., Ltd. | Dérivés de sulfonamide et leurs applications pharmaceutiques |
CN105367472B (zh) * | 2014-08-12 | 2020-04-21 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
CN105367473B (zh) * | 2014-08-12 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
JP2018520187A (ja) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 |
CN108926565A (zh) * | 2017-05-26 | 2018-12-04 | 中国科学院上海生命科学研究院 | 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用 |
WO2019180176A1 (fr) | 2018-03-21 | 2019-09-26 | Spherium Biomed, S.L. | Composition pour le traitement de la schizophrénie et/ou de la psychose |
US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE81861C (fr) | ||||
NZ193654A (en) * | 1979-05-16 | 1984-08-24 | Wuelfing Johann A | Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions |
US4315014A (en) * | 1980-09-24 | 1982-02-09 | Warner-Lambert Company | Antibacterial amide compounds and pharmaceutical composition containing the same |
EP0076072B1 (fr) * | 1981-09-24 | 1987-05-13 | BEECHAM - WUELFING GmbH & Co. KG | Sulfonamides |
CN85106905A (zh) * | 1985-08-08 | 1987-02-04 | Fmc公司 | 含有1-芳基-δ2-1,2,4,-***啉-5-酮类的除草剂及其制备方法 |
AU5175490A (en) * | 1989-02-27 | 1990-09-26 | Du Pont Merck Pharmaceutical Company, The | Novel sulfonamides as radiosensitizers |
JPH04330057A (ja) * | 1991-05-01 | 1992-11-18 | Hiroyoshi Hidaka | アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩 |
GB9119932D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
DE4206531A1 (de) * | 1992-03-02 | 1993-09-09 | Bayer Ag | N-aryl-stickstoffheterocyclen |
DE4303376A1 (de) * | 1993-02-05 | 1994-08-11 | Bayer Ag | Substituierte Triazolinone |
DE69417427T2 (de) * | 1993-09-03 | 1999-11-25 | Smithkline Beecham Plc | Indol- und indolin-derivate als 5ht1d rezeptor antagonisten |
WO1995011243A1 (fr) * | 1993-10-19 | 1995-04-27 | Smithkline Beecham Plc | Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d |
US5801170A (en) * | 1993-12-07 | 1998-09-01 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5HT1D antagonists |
AU2565595A (en) * | 1994-05-28 | 1995-12-21 | Smithkline Beecham Plc | Amide derivatives having 5ht1d-antagonist activity |
US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
-
1997
- 1997-12-07 DZ DZ970226A patent/DZ2376A1/fr active
- 1997-12-15 EA EA199900561A patent/EA002351B1/ru not_active IP Right Cessation
- 1997-12-15 IL IL13029797A patent/IL130297A0/xx unknown
- 1997-12-15 ID IDW990546A patent/ID22821A/id unknown
- 1997-12-15 AU AU60904/98A patent/AU729056B2/en not_active Ceased
- 1997-12-15 SK SK808-99A patent/SK80899A3/sk unknown
- 1997-12-15 PL PL97334337A patent/PL334337A1/xx unknown
- 1997-12-15 CA CA002275492A patent/CA2275492A1/fr not_active Abandoned
- 1997-12-15 ES ES97954929T patent/ES2203831T3/es not_active Expired - Lifetime
- 1997-12-15 KR KR1019997005497A patent/KR20000069554A/ko not_active Application Discontinuation
- 1997-12-15 HU HU0000658A patent/HUP0000658A3/hu unknown
- 1997-12-15 CN CN97181816A patent/CN1246116A/zh active Pending
- 1997-12-15 TR TR1999/01361T patent/TR199901361T2/xx unknown
- 1997-12-15 JP JP52734798A patent/JP2001506646A/ja not_active Ceased
- 1997-12-15 AP APAP/P/1999/001556A patent/AP1277A/en active
- 1997-12-15 DE DE69724142T patent/DE69724142T2/de not_active Expired - Fee Related
- 1997-12-15 AT AT97954929T patent/ATE247099T1/de not_active IP Right Cessation
- 1997-12-15 BR BR9713734-0A patent/BR9713734A/pt not_active IP Right Cessation
- 1997-12-15 CZ CZ992203A patent/CZ220399A3/cs unknown
- 1997-12-15 WO PCT/EP1997/007159 patent/WO1998027081A1/fr not_active Application Discontinuation
- 1997-12-15 NZ NZ335970A patent/NZ335970A/en unknown
- 1997-12-15 EP EP97954929A patent/EP0946539B1/fr not_active Expired - Lifetime
- 1997-12-17 PE PE1997001126A patent/PE46899A1/es not_active Application Discontinuation
- 1997-12-17 MA MA24902A patent/MA24426A1/fr unknown
- 1997-12-17 AR ARP970105951A patent/AR010795A1/es not_active Application Discontinuation
- 1997-12-18 TW TW086119136A patent/TW418205B/zh not_active IP Right Cessation
- 1997-12-18 UY UY24819A patent/UY24819A1/es not_active Application Discontinuation
-
1999
- 1999-06-18 NO NO993003A patent/NO993003D0/no not_active Application Discontinuation
- 1999-06-18 OA OA9900133A patent/OA11066A/en unknown
- 1999-06-25 BG BG103530A patent/BG103530A/bg unknown
-
2000
- 2000-08-21 US US09/643,200 patent/US6423717B1/en not_active Expired - Fee Related
-
2002
- 2002-05-29 US US10/157,258 patent/US6599904B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ2376A1 (fr) | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. | |
DZ2457A1 (fr) | Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. | |
DZ2197A1 (fr) | Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2407A1 (fr) | Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2300A1 (fr) | Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2299A1 (fr) | Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2634A1 (fr) | Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant. | |
DZ2758A1 (fr) | Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2891A1 (fr) | Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2621A1 (fr) | AGonistes de prostaglandines nouveaux procédé pourleur préparation et compositions pharmaceutiques les contenant. | |
DZ1889A1 (fr) | Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2666A1 (fr) | Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
MA26659A1 (fr) | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26432A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
DZ1957A1 (fr) | Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2198A1 (fr) | Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant. | |
DZ3042A1 (fr) | Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
FR2718136B1 (fr) | Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant. | |
DZ2870A1 (fr) | Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant. | |
MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
DZ2227A1 (fr) | Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant. | |
DZ2777A1 (fr) | Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
MA26558A1 (fr) | Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation |